Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer

BACKGROUND: EGFR tyrosine kinase inhibitor (TKI) is recommended as the first-line therapy for patients with EGFR-mutant metastatic non-small cell lung cancer (NSCLC). Yet, resistance often occurs in 1 year after therapy and most progressions occur at the initial sites of disease. Addition of local t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xiaotong, Wang, Jingbo, Wang, Chunyu, Liang, Jun, Zhou, Zongmei, Chen, Dongfu, Feng, Qinfu, Xiao, Zefen, Hui, Zhouguang, Lu, Jima, Zhang, Tao, Liu, Wenyang, Wang, Jianyang, Wang, Xin, Deng, Lei, Zhai, Yirui, Bi, Nan, Wang, Luhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891891/
https://www.ncbi.nlm.nih.gov/pubmed/35250326
http://dx.doi.org/10.1177/11795549221080347

Ejemplares similares

Ejemplares similares